Shuai Li

Shuai Li

Auto-generated profile, based on publicly available information

Shuai Li

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education / Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing Cancer Hospital & Institute, Beijing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Radiotherapy and Oncology
Verified
Journal Article
Open access
YZYang-Zi Zhang
Yang-Zi Zhang
MSMaxiaowei Song
Maxiaowei Song
JGJian-Hao Geng
Jian-Hao Geng
XZXiang-Gao Zhu
Xiang-Gao Zhu
SLShuai Li
Shuai Li
WWWei-Hu Wang
Wei-Hu Wang
Elective irradiation of the external iliac lymph nodes (EIN) has always been advocated for T4b rectal cancer with anterior organ invasion without convincing evidence. This study aimed to explore the patterns of treatment failure for locally advanced T4b rectal cancer treated using neoadjuvant chemoradiotherapy (NCRT) and surgery. This information may help to clarify whether the current definition of the clinical target volume (CTV) is still appropriate. We retrospectively analyzed data from 126 patients with locally advanced T4b rectal cancer who received NCRT, without elective EIN irradiation, followed by surgery between January 2010 and October 2018. Pretreatment magnetic resonance imaging was used to identify the T4b disease in all cases. The locoregional recurrence (LRR) rate and EIN failure rate were evaluated, and the LRR locations were identified using a three-dimensional model. After a median follow-up of 53.9 months, LRR occurred in 11.1% of patients (14/126). All LRRs were located in the previously irradiated fields and below the S2-S3 junction. The EIN failure rate was 0.8% (1/126) among all patients and 1.8% (1/56) in the group with anterior genitourinary organ invasion. The estimated 4-year distant relapse-free survival, disease-free survival and overall survival were 79.3%, 73.2% and 86.9%, respectively. It may be feasible to exclude the external iliac region from the CTV during NCRT for locally advanced T4b rectal cancer. However, further studies are needed to clarify whether the cranial border of the CTV can be lowered.

1 January 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SLShuai Li
Shuai Li
JGJianhao Geng
Jianhao Geng
LWLin Wang
Lin Wang
HTHuajing Teng
Huajing Teng
ZWZhilong Wang
Zhilong Wang
WWWei-Hu Wang
Wei-Hu Wang
Background: We aimed to analyze the effect of simultaneous integrated boost intensity modulated radiation therapy (SIB-IMRT) and non-operative treatment on the clinical outcomes of distal rectal cancer patients exhibiting clinically positive lateral pelvic lymph nodes (LPLNs). Methods: We reviewed the medical records of patients diagnosed as having distal rectal adenocarcinoma with clinically positive LPLNs (≥ 7 mm, with irregular borders or mixed signal intensity) using primary pelvic magnetic resonance imaging (MRI). These patients had received SIB-IMRT-based neoadjuvant chemoradiotherapy (NCRT) and non-operative treatment according to the heterogeneity of the disease or personal preference. Chi-square tests were used to compare data between the two groups. Progression-free survival (PFS) and local regrowth were evaluated using the Kaplan-Meier method. Results: Between 2016 and 2019, we analyzed 75 patients diagnosed as having clinically positive LPLNs using primary MRI. SIB-IMRT was delivered to the planning positive LPLNs (PGTVn) at a total dose of 56– 60 Gy. After NCRT, 23 patients underwent non-operative treatment. Among these patients, the median short axis of LPLNs was 8 mm (range: 7– 21 mm). Fifteen patients were categorized into the mesorectal fascia (MRF)-positive group. The median follow-up duration for these patients was 19.8 months, and no patient exhibited LPLN regrowth. The 2-year PFS rate was 85.6% for non-operative patients, 74.6% for operative patients, and 90.0% for the pathological complete response (pCR) subgroup. Eighteen patients who underwent non-operative treatment were included in the clinical complete response (cCR) subgroup. The 2-year PFS and local regrowth rates in this group were similar to those in patients with clinically negative LPLN who achieved cCR. During NCRT, 21 (28.0%) patients experienced grade 2– 3 acute reversible toxicity. Conclusions: SIB-IMRT could eliminate metastases in LPLNs in a safe and effective manner, and non-operative strategies may be promising for cCR patients.

1 May 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
ZSZhuo Song
Zhuo Song
XZXuan Zheng
Xuan Zheng
HWHongzhi Wang
Hongzhi Wang
DDDezuo Dong
Dezuo Dong
XZXianggao Zhu
Xianggao Zhu
WWWei-Hu Wang
Wei-Hu Wang
Purpose: This study explored the efficacy and safety of combining systemic therapy with stereotactic body radiotherapy (SBRT) for oligoprogressive (OP) and oligometastatic (OM) hepatocellular carcinoma (HCC). Patients and Methods: From January 2017 to June 2023, 37 HCC patients (28 OP, 9 OM) receiving systemic therapy and SBRT were identified. OP is defined as up to 5 progressive lesions with others stable after systemic therapy and OM as newly identified metastatic disease with up to 5 metastatic lesions. SBRT was delivered in fractions of 5 Gy or more to all lesions. Clinical outcomes and toxicity were evaluated. Results: The median follow-up was 32.8 months. The objective response rates (ORRs) were 47.2%, 44.4%, and 55.5% for overall, OP, and OM cohorts. SBRT treated 48 OP and 17 OM lesions, achieving an ORR of 64.7%. For overall, OP, and OM cohorts, the 2-year local failure rates were 3.0%, 4.0%, and 0%, with median progression-free survival (PFS) of 11.2, 11.2, and 10.2 months, and median overall survival (OS) of 34.9 months, 32.6 months, and not reached (NR), respectively. In the OP cohort, 12 patients switched to next-line systemic therapy (OP-N) and 16 remained on current therapy (OP-C). Median PFS and OS were 11.6 months and NR for OP-N versus 16.5 months and 32.6 months for OP-C (P=0.89 and 0.47). Grade 3 acute and late treatment-related adverse events occurred in 40.5% and 5.4% of patients. Conclusion: Systemic therapy combined with SBRT was effective and safe for OP and OM HCC. SBRT may delay next-line systemic therapy by blocking OP. Plain Language Summary: Combining systemic therapy with stereotactic body radiotherapy (SBRT) represents a promising treatment strategy for oligoprogressive (OP) and oligometastatic (OM) hepatocellular carcinoma.This study demonstrates that SBRT combined with systemic therapy may offer favorable short-term response and long-term outcomes while maintaining a good safety profile.OP patients who continue their current systemic therapy while receiving SBRT may block OP status and achieve outcomes comparable to those who switch therapies, highlighting the potential of this approach to delay treatment changes and improve outcomes.

1 August 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SLSha Li
Sha Li
ZLZhengxian Li
Zhengxian Li
SLShuai Li
Shuai Li
PJPing Jiang
Ping Jiang
HHHongbin Han
Hongbin Han
YLYanye Lu
Yanye Lu
Objective: Accurately identifying patients achieving pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC) not only ensures treatment efficacy but also helps avoid surgical risks. We developed a comprehensive multi-omics model to predict pCR before surgery. Methods: Clinical data, CT, MRI-T1WI and MRI-T2WI, and radiotherapy dose were collected from 183 LARC patients who underwent preoperative nCRT. Backward stepwise selection, logistic regression, and five-fold cross-validation were employed for the development and validation of a non-imaging model, three radiomics-based models and a dosiomics-based model. These were integrated into a final model, and its performance was tested on multi-center sets. Results: C_model, based on clinical characteristics, achieved an AUC of 0.85 in the validation set. Radiomics models (CT_model, T1_model, T2_model) exhibited AUCs of 0.66, 0.67, and 0.64, respectively. Dosiomics-based model, D_model, achieved an AUC of 0.75 in validation. The mean AUCs for F_model in the training sets, validation sets, internal and external test sets were 0.90, 0.88, 0.77, and 0.74, respectively. Conclusion: To assess the efficacy of nCRT in LARC patients, it is crucial to consider clinical characteristics, followed by dosiomics. While T1_model, T2_model and CT_model demonstrate relatively comparable performance, each contributes unique value to the final prediction model.